First Tracks Biotherapeutics Inc
TRAXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 4, 2026 | Guggenheim | Yatin Suneja | $110.00(+137%) | $46.34 | StreetInsider |
| Oct 13, 2026 | Evercore ISI | $70.00(+118%) | $32.06 | TheFly | |
| Oct 13, 2026 | Canaccord Genuity | $60.00(+76%) | $34.05 | TheFly | |
| Oct 12, 2026 | Wells Fargo | Derek Archila | $70.00(+106%) | $34.05 | TheFly |
| Oct 9, 2026 | Wells Fargo | $62.00(+94%) | $32.01 | TheFly | |
| Sep 30, 2026 | Canaccord Genuity | $50.00(+39%) | $35.98 | TheFly | |
| Sep 18, 2026 | Evercore ISI | $65.00(+66%) | $39.20 | TheFly | |
| Sep 16, 2026 | Guggenheim | $100.00(+160%) | $38.47 | TheFly | |
| Aug 13, 2026 | Piper Sandler | $95.00(+106%) | $46.13 | TheFly | |
| Aug 13, 2026 | H.C. Wainwright | $57.00(+24%) | $46.13 | TheFly | |
| Aug 13, 2026 | Barclays | $65.00(+41%) | $46.13 | TheFly | |
| Aug 10, 2026 | UBS | $65.00(+39%) | $46.83 | TheFly | |
| Jul 28, 2026 | Wedbush | $60.00(+43%) | $41.92 | TheFly | |
| Jul 28, 2026 | Wells Fargo | Derek Archila | $55.00(+31%) | $42.03 | TheFly |
| Jul 21, 2026 | Barclays | $48.00(+30%) | $36.87 | TheFly | |
| Jul 10, 2026 | H.C. Wainwright | Emily Bodnar | $44.00(+36%) | $32.40 | TheFly |
| Jun 8, 2026 | Wells Fargo | Derek Archila | $30.00(+81%) | $16.60 | TheFly |
| May 4, 2026 | Piper Sandler | Yasmeen Rahimi | $54.00(+141%) | $22.38 | TheFly |
| Apr 28, 2026 | H.C. Wainwright | Emily Bodnar | $30.00(+66%) | $18.10 | TheFly |
| Apr 24, 2026 | Leerink Partners | David Risinger | $46.00(+142%) | $19.00 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Guggenheim | maintain | Buy | Nov 4, 2026 |
| Leerink Partners | maintain | Outperform | Oct 16, 2026 |
| Canaccord Genuity | maintain | Buy | Oct 13, 2026 |
| Evercore ISI Group | maintain | Outperform | Oct 13, 2026 |
| Wells Fargo | maintain | Overweight | Oct 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | Sep 3, 2026 |
| Barclays | maintain | Overweight | Aug 13, 2026 |
| Wedbush | maintain | Outperform | Aug 13, 2026 |
| Piper Sandler | maintain | Overweight | Aug 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 13, 2026 |
| UBS | maintain | Buy | Aug 10, 2026 |
| Wedbush | maintain | Outperform | Jul 28, 2026 |
| Wells Fargo | maintain | Overweight | Jul 28, 2026 |
| Barclays | maintain | Overweight | Jul 21, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 10, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 8, 2026 |
Earnings History
Next report: Feb 2, 2027 · EPS est. $-0.75| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 3, 2026 | $-0.88 | $-0.90 | — | — |
| Aug 12, 2026 | $-0.95 | $-0.80 | — | $75.0M |
| May 14, 2026 | $-1.45 | $-0.98 | — | $22.3M |
News
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the third quarter ended Sept. 30, 2026, and provided a business update.
SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 6,106,870 shares of its common stock to a limited group of institutional investors in a private placement at a price of $32.75 per share. First Tracks Biotherapeutics ant…
First Tracks Biotherapeutics offers a differentiated CD122 antagonist, ANB033, showing promising Phase 1b data in celiac disease with statistically significant histology and symptom improvements. TRAX's ANB033 demonstrated a stronger efficacy signal versus Teva's IL-15 inhibitor, with a more pronounced reduction in mucosal injury and symptom severity under a harsher gluten challenge. With $168M in cash and a projected runway into Q2 2028, TRAX is positioned for late-stage celiac trials and expan…
First Tracks Biotherapeutics (NASDAQ: TRAX) reported top-line results from the first cohort of its Phase Ib study of ANB033 in celiac disease, saying the investigational CD122 antagonist met histologic and symptom-related objectives during a placebo-controlled gluten challenge. The cohort enrolled 32 patients with celiac disease, including 17 who received ANB033 and 15 who received placebo. Participants
First Tracks Biotherapeutics NASDAQ: TRAX reported top-line results from the first cohort of its Phase Ib study of ANB033 in celiac disease, saying the investigational CD122 antagonist met histologic and symptom-related objectives during a placebo-controlled gluten challenge.
U.S. stocks were mixed, with the Dow Jones index gaining around 100 points on Monday.
SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday…
First Tracks Biotherapeutics (NASDAQ: TRAX - Get Free Report) Director J. Anthony Ware sold 39,265 shares of the firm's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $44.78, for a total transaction of $1,758,286.70. Following the completion of the transaction, the director directly owned 15,660 shares of
SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:
First Tracks Biotherapeutics Inc (NASDAQ:TRAX) reported a narrower loss for the second quarter on Wednesday.
SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.